Article Text

Download PDFPDF
  1. Tatyana V. Gorodnova, MD, PhD*,
  2. Khristina B. Kotiv, MD*,
  3. Alexandr O. Ivantsov, MD, PhD*,
  4. Olga N. Mikheyeva, MD,
  5. Galina I. Mikhailiuk, MD,
  6. Alla S. Lisyanskaya, MD,
  7. Nikolay A. Mikaya, MD*,
  8. Konstantin D. Guseynov, MD, PhD*,
  9. Nikolay E. Bondarev, MD*,
  10. Nataliya S. Matveyeva, MD*,
  11. Ekatherina A. Nekrasova, MD*,
  12. Anna A. Sidoruk, MD*,
  13. Laslo D. Roman, MD, PhD,
  14. Georgiy M. Manikhas, MD, PhD,
  15. Alexey M. Belyaev, MD, PhD*,
  16. Anna P. Sokolenko, MD, PhD*,§,
  17. Igor V. Berlev, MD, PhD* and
  18. Evgeny N. Imyanitov, MD, PhD*,§
  1. *N.N. Petrov Institute of Oncology;
  2. Leningrad Regional Oncological Dispensary;
  3. City Oncological Dispensary; and
  4. §St. Petersburg Pediatric Medical University, St. Petersburg, Russia.
  1. Address correspondence and reprint requests to Evgeny N. Imyanitov, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg 197758, Russia. E-mail: evgeny{at}


Objectives Cisplatin and mitomycin C exert high activity towards BRCA1-deficient cells. This study aimed to evaluate the efficacy of a combination of these drugs in hereditary BRCA1-associated ovarian cancer (OC).

Methods Twelve OC patients, who could not be treated by primary debulking surgery owing to extensive tumor spread, were given neoadjuvant cisplatin (100 mg/m2) and mitomycin C (10 mg/m2) every 4 weeks for 3 (n = 9), 2 (n = 2), or 4 (n = 1) cycles.

Results The decrease of tumor burden and complete surgical cytoreduction were achieved in all patients. Pathologic complete response, defined as the absence of tumor cells in surgically removed tissues, was observed in 2 (17%) of 12 cases. Retrospective analysis of 62 OC in BRCA1 mutation carriers subjected to conventional neoadjuvant chemotherapy schemes revealed 36 objective tumor responses (58%) and 37 instances (60%) of complete cytoreductive surgery; however, none of these patients demonstrated pathologic complete response.

Conclusions The combination of cisplatin plus mitomycin C showed promising results in BRCA1-driven OC and therefore deserves further clinical evaluation.

  • BRCA1
  • Mitomycin C
  • Mutation
  • Neoadjuvant therapy
  • Ovarian cancer
  • Clinical trial

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • This work has been supported by the Russian Science Foundation (grant number 14-25-00111).

  • The authors declare no conflicts of interest.